Solid Biosciences (SLDB) CEO awarded options and RSUs, sells shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Solid Biosciences Inc.’s President and CEO Alexander Cumbo reported multiple equity compensation events and a tax-related share sale. On January 29, 2026, 169,401 performance stock units vested into common shares, he received an option grant for 509,850 shares at $6.60, and was granted 254,900 RSUs.
On January 31, 2026, 100,400 RSUs from a prior grant vested into common stock. On February 2, 2026, Cumbo sold 80,258 shares at a weighted average price of $6.4369 to cover withholding taxes under an automatic sell-to-cover instruction, leaving him with 270,931 directly held common shares plus unvested RSUs and options.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 80,258 shares ($516,613)
Net Sell
7 txns
Insider
Cumbo Alexander
Role
President and CEO
Sold
80,258 shs ($517K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 80,258 | $6.4369 | $517K |
| Exercise | Restricted Stock Units | 100,400 | $0.00 | -- |
| Exercise | Common Stock | 100,400 | $0.00 | -- |
| Exercise | Performance Stock Units | 169,401 | $0.00 | -- |
| Grant/Award | Employee Stock Option (Right to Buy) | 509,850 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 254,900 | $0.00 | -- |
| Exercise | Common Stock | 169,401 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 270,931 shares (Direct);
Restricted Stock Units — 301,200 shares (Direct);
Performance Stock Units — 0 shares (Direct);
Employee Stock Option (Right to Buy) — 509,850 shares (Direct)
Footnotes (1)
- Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis. Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis. This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Mr. Cumbo on August 18, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Cumbo. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form. The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares. This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary. The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary. On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 401,600 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary.
FAQ
What did Solid Biosciences (SLDB) CEO Alexander Cumbo report in this Form 4?
Alexander Cumbo reported vesting of performance and restricted stock units, a new stock option grant, and a related tax sale. PSUs and RSUs converted into common stock, he received 509,850 options, and some shares were sold automatically to satisfy withholding tax obligations.
What new equity awards did Solid Biosciences grant to CEO Alexander Cumbo?
Cumbo received a stock option for 509,850 shares at a $6.60 exercise price and a grant of 254,900 restricted stock units on January 29, 2026. Both awards vest over four years, with 25% vesting after one year and the remainder vesting in periodic installments.